Advertisement

Related Videos

Russell Szmulewitz, MD, on Alternative Dosing of Abiraterone in Prostate Cancer: Pharmacoeconomic Proof of Concept

R. Donald Harvey, PharmD, BCOP, FCCP, FHOPA, on Alternative Dispensing Strategies

Focus on Optimized Dosing of Ibrutinib Panel Discussion

David T. Rubin, MD, on Biosimilars for Inflammatory Bowel Disease

Mark Sculpher, PhD: How Do We Assess the Value of Cancer Drug Optimization?

Advertisement

Advertisement




Jan
25
Today In Oncology
Prostate Cancer: Novel PSMA-Targeted Radioligand Shows Reduced Salivary Gland Uptake in Preclinical Studies
HCC LLM Advice and Treatment Concordance
Medical Societies Caution Misinformation May Drive Underuse of Lung Cancer Screening
Atezolizumab vs Placebo With Bevacizumab and Nonplatinum Chemotherapy for Recurrent Ovarian Cancer
ChatGPT May Accurately Answer Common Patient Questions Regarding Gynecologic Cancer
View More 
Advertisement
© 2026 HSP News Service, L.L.C.
Conexiant Oncology Logo